Results 191 to 200 of about 146,739 (334)

Surface Engineering of Thrombus‐Targeting Nanocarriers for Cardiovascular Diseases: A Short Review

Advanced Materials Interfaces, Volume 12, Issue 13, July 14, 2025.
This paper systematically introduces surface modification strategies for thrombus‐targeting nanocarriers, highlights the clinical significance of nanocarrier‐based thrombolysis therapies, and prospects the synergy of combing thrombolysis and anti‐inflammatory therapies for enhanced therapeutic effect.
Xinyue Ge, Lei Ding, Wenjun Zhao, Bohan Cui, Xiang Guan, Mingfei Pan, Qingguo Li, Ning Gu   +7 more
wiley   +1 more source

Delayed epidural hematoma after spinal cord stimulator implantation in a patient with von Willebrand disease: Illustration. [PDF]

Surg Neurol Int
Jaffee S, Mamadhi J, Kite T, Kramer DE, Tomycz N.   +4 more
europepmc   +1 more source

Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma) [PDF]

, 2001
A Scheja, Anita Åkesson, Pierre Geborek, Marie Wildt, Claes B. Wollheim, Frank A. Wollheim, Ulrich M. Vischer   +6 more
openalex   +1 more source

Catastrophic Neurological Collapse Following Push‐Up Exercise: A Rare Case of Spontaneous Hematomyelia Causing Acute Paraplegia in a Healthy Young Adult

Clinical Case Reports, Volume 13, Issue 7, July 2025.
ABSTRACT Spontaneous hematomyelia, or non‐traumatic intramedullary spinal cord hemorrhage, is a rare and potentially devastating neurological condition. Unlike hematomyelia resulting from overt trauma, spontaneous cases occur in the absence of significant injury and present substantial diagnostic and therapeutic challenges.
Yegzeru Belete, Abera Kuma, Amanuel Anegagregn, Abdulkerim Girma   +3 more
wiley   +1 more source

Global prevalence of platelet-type von Willebrand disease. [PDF]

Res Pract Thromb Haemost
Seidizadeh O, Cairo A, Othman M, Peyvandi F.   +3 more
europepmc   +1 more source

Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease

, 1995
Hiroyuki Takahashi, Mitsuru Murata, Toshiaki Moriki, Hironobu Anbo, T Furukawa, Koji Nikkuni, Akira Shibata, Makoto Handa, Y Kawai, Kazuhiro Watanabe   +9 more
openalex   +1 more source

Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development [PDF]

, 2001
Gurcharan K. Surdhar, M. S. Enayat, Sarah Lawson, Michael D. Williams, Frank G. H. Hill   +4 more
openalex   +1 more source

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 860-872, July 2025.
Abstract Efanesoctocog alfa is a first‐in‐class high‐sustained factor VIII (HSF) replacement therapy for treatment of hemophilia A. This article presents population pharmacokinetics (PopPK) of efanesoctocog alfa and repeated time‐to‐event (RTTE) analysis of bleeding episodes in adults/adolescents (≥12 years of age) and children (<12 years).
Nancy Wong, Pratik Bhagunde, Joakim Nyberg, Suresh Katragadda, Marek Demissie, Annemieke Willemze, Craig Benson, Sreeraj Macha   +7 more
wiley   +1 more source

Challenges and considerations of genetic testing in von Willebrand disease. [PDF]

Res Pract Thromb Haemost
Seidizadeh O, Baronciani L, Peyvandi F.
europepmc   +1 more source

Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study

, 1999
A. Rumley, G.D.O. Lowe, P M Sweetnam, J. W. G. Yarnell, R P Ford   +4 more
openalex   +1 more source